Wietse Vanpoucke
Overview
Wietse Vanpoucke’s practice focuses on the life sciences and digital health sectors. His diverse set of clients, which include innovative startups and multinational corporations, rely on his deep experience with European and Belgian regulatory affairs and legal procedures. Wietse's interests include emerging technologies, such as artificial intelligence, blockchain, and the Internet of Medical Things, and he diligently tracks legal developments impacting these areas.
Career & Education
- Karel de Grote Hogeschool, B.A., cum laude, social work, 2016
- Vrije Universiteit Brussel, J.D., magna cum laude, 2020
- University of Leeds, LL.M., distinction, comparative corporate and financial law, 2020
- Belgium
- Dutch
- English
- French
Wietse's Insights
Client Alert | 6 min read | 07.25.24
The EU legal and policy framework regarding critical medicines and medicine shortages is rapidly changing. In the past 12 months alone, there have been numerous developments: from the ‘Non-Paper’; to the Communication on ‘Addressing medicine shortages’; and the launch of the Critical Medicines Alliance. In the next 12 months, there is likely to be similar developments – including a possible draft proposal for a ‘Critical Medicines Act’. As the new regulatory framework becomes clearer, pharma companies will need to understand it, and prepare for the impact it will have.
Client Alert | 22 min read | 05.31.24
2024: An Overview of New and Upcoming Belgian and EU Laws and Regulations – UPDATED in May 2024
Client Alert | 19 min read | 01.31.24
2024: An Overview of New and Upcoming Belgian and EU Laws and Regulations
Insights
Digital Health Laws and Regulations – Belgium
|01.01.22
International Comparative Legal Guide
Digital Healthcare 2022 – Belgium
|01.01.22
Chambers and Partners
Copyright Challenged by Art Created by Artificial Intelligence
|01.01.21
European Intellectual Property Review, Volume 43, Issue 8
Wietse's Insights
Client Alert | 6 min read | 07.25.24
The EU legal and policy framework regarding critical medicines and medicine shortages is rapidly changing. In the past 12 months alone, there have been numerous developments: from the ‘Non-Paper’; to the Communication on ‘Addressing medicine shortages’; and the launch of the Critical Medicines Alliance. In the next 12 months, there is likely to be similar developments – including a possible draft proposal for a ‘Critical Medicines Act’. As the new regulatory framework becomes clearer, pharma companies will need to understand it, and prepare for the impact it will have.
Client Alert | 22 min read | 05.31.24
2024: An Overview of New and Upcoming Belgian and EU Laws and Regulations – UPDATED in May 2024
Client Alert | 19 min read | 01.31.24
2024: An Overview of New and Upcoming Belgian and EU Laws and Regulations
